UPDATE: FDA Approves Amylin's Bydureon Diabetes Drug After Delays
January 27 2012 - 4:46PM
Dow Jones News
The U.S. Food and Drug Administration approved Amylin
Pharmaceuticals Inc.'s (AMLN) diabetes drug Bydureon after a
prolonged regulatory process in which the agency required extra
testing to alleviate safety concerns.
Bydureon is the first once-weekly treatment for type 2 diabetes,
the most common form of diabetes, Amylin and its partner Alkermes
Inc. (ALKS), which developed the extended-release technology for
Bydureon, said in a press release Friday. The companies said the
drug will be available in U.S. pharmacies in February.
The FDA-approved prescribing label for Bydureon has a prominent
warning stating that the drug caused certain kinds of thyroid
tumors in rats at clinically relevant exposures in testing,
according to the FDA website.
The warning notes that it's unknown whether the drug causes such
tumors in humans. But it says Bydureon shouldn't be used in
patients with a personal or family history of medullary thyroid
carcinoma.
Bydureon is an injectable, extended-release version of Amylin's
older diabetes drug, Byetta, which is injected twice daily. Byetta
and Bydureon share an active ingredient, exenatide. Bydureon was
approved for sale by European regulators in June.
The drug is designed to work by helping the body to make more
insulin, which can reduce high blood-sugar levels.
"As the first and only once-weekly diabetes treatment, Bydureon
represents an important milestone in Amylin's promise to bring to
market innovative therapies to help improve the lives of people
with type 2 diabetes," Amylin Chief Executive Daniel Bradbury said
in a press release.
Some analysts have estimated Bydureon sales could reach nearly
$2 billion annually by the end of this decade. But it will face a
crowded market, as drug companies have responded to the rising
incidence of diabetes worldwide by developing new treatments.
One competitor is Novo Nordisk A/S's (NVO) Victoza, a once-daily
injectable drug. Although a once-weekly drug like Bydureon might
seem more convenient for patients than once-daily, a study released
last year showed that Victoza reduced blood-sugar levels to a
greater degree than Bydureon.
Bydureon's road to FDA approval was a bumpy one, along which
Amylin severed its longstanding diabetes-drug partnership with Eli
Lilly & Co. (LLY). Amylin first began working on Bydureon in
1999. The original plan was for Lilly and Amylin to co-promote
Bydureon in the U.S., with Lilly handling markets outside the U.S.
The companies had a similar arrangement for Byetta, which was
approved by the FDA in 2005.
Lilly and Amylin submitted Bydureon for FDA approval in May
2009, based on clinical-trial data showing it improved measures of
blood sugar versus Byetta. Addressing heightened FDA scrutiny of
heart-related effects of diabetes drugs, the companies said at the
time that an analysis showed no increased risk of cardiovascular
events to be associated with exenatide.
The FDA initially declined to approve it, asking in March 2010
for more information about the drug's prescribing label and the
companies' risk-management plan to ensure the drug's benefits
outweigh its risks. Amylin and Lilly were optimistic they would get
FDA approval later in 2010 after providing the requested
information.
However, in October 2010, the FDA dropped a bombshell by
rejecting Bydureon again. This time the agency asked for a new
study to test the effect of a high dose of the drug on heart
rhythm.
The companies ran the required test and in June said results
showed Bydureon wasn't associated with a clinically relevant
prolonged measure of heart rhythm. The results increased optimism
that the drug would finally get an FDA green light.
Amid the delay, the partnership between Lilly and Amylin
deteriorated, and ultimately was terminated. In January 2010, Lilly
formed a new diabetes-drug partnership with Boehringer Ingelhiem
GmbH, prompting Amylin to file a lawsuit alleging breach of its own
contract with Lilly.
In November, Lilly and Amylin settled the dispute by agreeing to
return global development and commercialization rights for Byetta
and Bydureon to Amylin. Lilly will receive royalties on sales of
Byetta and Bydureon up to a cap.
The FDA approval for Bydureon requires Amylin to conduct
additional testing to further assess the drug's impact on thyroid
cancer and cardiovascular disease.
Shares of Amylin and Alkermes were halted Friday in advance of
the agency decision.
-By Peter Loftus, Dow Jones Newswires; 215-982-5581;
peter.loftus@dowjones.com
--Jennifer Corbett Dooren contributed to this article.
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024